• Bionano Genomics flagged 13 independent 2026 publications on optical genome mapping in reproductive health and prenatal genetic disorders, covering 730 samples.
• Results have already been presented in published papers, with some studies reanalyzing previously inconclusive cases.
• Across the studies, optical genome mapping improved detection of genetic causes in infertility and pregnancy-loss research compared with prior standard testing.
• In prenatal settings, findings generally aligned with standard diagnostics while also uncovering additional clinically relevant structural changes missed previously.
• The body of evidence strengthens the case for broader research and potential clinical adoption of the company’s platform in reproductive medicine workflows.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionano Genomics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110800PRIMZONEFULLFEED9735260) on June 11, 2026, and is solely responsible for the information contained therein.